about
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA.Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis.eis Promoter C14G and C15G Mutations Do Not Confer Kanamycin Resistance in Mycobacterium tuberculosis.Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes.Plasma drug activity in patients on treatment for multidrug-resistant tuberculosisDiscordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.Primary multidrug-resistant Mycobacterium tuberculosis in 2 regions, Eastern Siberia, Russian Federation.18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series.Plasma drug activity assay for treatment optimization in tuberculosis patients.Comparison of overnight pooled and standard sputum collection method for patients with suspected pulmonary tuberculosis in northern Tanzania.Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.Rapid first- and second-line drug susceptibility assay for Mycobacterium tuberculosis isolates by use of quantitative PCR.Mycobacterial infections in a large Virginia hospital, 2001-2009.The future of molecular diagnostics for drug-resistant tuberculosis.Correction: Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.Optimizing second-line therapy for drug-resistant tuberculosis: the additive value of sequencing for multiple resistance loci.Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural TanzaniaEvaluation of cytokines in peripheral blood mononuclear cell supernatants for the diagnosis of tuberculosis
P50
Q28487970-D16DB27B-70F4-4B1B-96C8-5351EB914AB5Q28543642-54DF6211-8BD1-4FEC-B144-767FA24C4C52Q28545109-8C3CB7C2-0546-4E13-B7E2-4CCAE8BDE9B3Q30252340-A6E0109E-F5E6-4369-BE8A-72F0D470906DQ30274831-1F56C6C4-D766-45A0-9B37-911366B37C64Q30275004-CC411441-C915-4E1A-8C18-C0926F12CB05Q30275565-442EB149-235A-4804-A68F-E9BE7D30DF58Q30278816-27BEDEB5-4BAB-405C-89FE-58F548F96DF7Q30300207-04DAC35B-6BC3-4493-B864-4E84E7FCC8D1Q30300560-8C4C2754-8186-41E4-B1A2-A1F7654C8A19Q30411475-E0E4E467-8678-4F43-82F9-1BBD8D80C5E7Q30414792-D5614ACD-68DC-414B-8154-A73EE4E2F997Q30415746-91B16204-2B43-4492-B420-0295A708D679Q30415943-A3B0A24A-581B-46CC-B0BD-63D8FFF484CDQ30416435-1D949C20-A1F6-43CF-81FD-57EABAAA30C1Q30419743-15644B25-80AA-4BB8-BDC1-276F9FD4C314Q30426583-9F74B80D-33BF-45D7-8CB4-DC87AE8C6BBDQ30426985-EB5220F5-9D26-47ED-89D1-D2549A328F90Q30427912-6C56EFE2-DDB8-4710-ABCD-1FB33C5462A4Q30431597-FDBEC47C-5788-4D4F-9A5E-C33E94B62576Q30432252-597E2A84-B374-4F22-9556-043299AEC81FQ30455525-F1C53588-245E-4BDD-B2ED-E32D09F6E609Q42331945-26E75E44-6D43-4766-A78A-D95FF58E65EAQ42849839-D59A8D23-8E3F-4B3B-8A9E-4D330D749B81Q49954429-8E62094B-FF4B-469C-8A71-0012EB7C769BQ54245604-1C0911D3-057B-4DE7-B42B-D4318B7E3739Q58611011-32B3509E-D73B-4A44-AF32-8FF013B687CEQ60935015-702BBD30-4661-4F66-8FD3-619DEEF08A46
P50
name
Scott K Heysell
@ast
Scott K Heysell
@en
Scott K Heysell
@nl
type
label
Scott K Heysell
@ast
Scott K Heysell
@en
Scott K Heysell
@nl
prefLabel
Scott K Heysell
@ast
Scott K Heysell
@en
Scott K Heysell
@nl